|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0045093,
umls-concept:C0069717,
umls-concept:C0205179,
umls-concept:C0242656,
umls-concept:C0281361,
umls-concept:C0282460,
umls-concept:C0332283,
umls-concept:C0449774,
umls-concept:C0694891,
umls-concept:C0995188,
umls-concept:C1517927,
umls-concept:C1559154,
umls-concept:C1707520
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2011-7-29
|
|
pubmed:abstractText |
This phase II trial was designed to assess the efficacy and safety of cetuximab, gemcitabine, and oxaliplatin followed by cetuximab, capecitabine, and radiation therapy in locally advanced pancreatic cancer (LAPC).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/SMAD4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Smad4 Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/cetuximab,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine,
http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AbbruzzeseJames LJL,
pubmed-author:CraneChristopher HCH,
pubmed-author:DasPrajnanP,
pubmed-author:FlemingJason BJB,
pubmed-author:HaqueWaqarW,
pubmed-author:HobbsBridgett DBD,
pubmed-author:JavleMilind MMM,
pubmed-author:KrishnanSunilS,
pubmed-author:LeeJeffrey EJE,
pubmed-author:SafranHowardH,
pubmed-author:StaerkelGregg AGA,
pubmed-author:VaradhacharyGauri RGR,
pubmed-author:WolffRobert ARA,
pubmed-author:YordyJohn SJS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3037-43
|
|
pubmed:dateRevised |
2011-8-30
|
|
pubmed:meshHeading |
pubmed-meshheading:21709185-Actuarial Analysis,
pubmed-meshheading:21709185-Adenocarcinoma,
pubmed-meshheading:21709185-Adult,
pubmed-meshheading:21709185-Aged,
pubmed-meshheading:21709185-Antibodies, Monoclonal,
pubmed-meshheading:21709185-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21709185-Chemotherapy, Adjuvant,
pubmed-meshheading:21709185-Deoxycytidine,
pubmed-meshheading:21709185-Disease Progression,
pubmed-meshheading:21709185-Drug Administration Schedule,
pubmed-meshheading:21709185-Female,
pubmed-meshheading:21709185-Humans,
pubmed-meshheading:21709185-Male,
pubmed-meshheading:21709185-Middle Aged,
pubmed-meshheading:21709185-Neoplasm Staging,
pubmed-meshheading:21709185-Organoplatinum Compounds,
pubmed-meshheading:21709185-Pancreatic Neoplasms,
pubmed-meshheading:21709185-Patient Selection,
pubmed-meshheading:21709185-Radiotherapy, Adjuvant,
pubmed-meshheading:21709185-Remission Induction,
pubmed-meshheading:21709185-Research Design,
pubmed-meshheading:21709185-Smad4 Protein,
pubmed-meshheading:21709185-Treatment Outcome,
pubmed-meshheading:21709185-Tumor Markers, Biological
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
|
|
pubmed:affiliation |
Dept of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX. ccrane@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
